Download prialt - Who we are

Alternative of Chronic Pain
Management proposed by
ELAN Pharmaceuticals, Inc.
Presented T. Chachibaia
2009. Nov.19
Pipeline and Products
Elan Corporation, plc is a neuroscience based biotechnology
company that is focused on discovering, developing,
manufacturing and marketing advanced therapies in
neurodegeneration, autoimmune diseases and severe pain.
TYSABRI (Crohn's Disease, Rheumatoid Arthritis) and
PRIALT (non-opioid analgesic) are registered trademarks of
Elan Pharmaceuticals, Inc.
AZACTAM and MAXIPIME (Infectious Diseases )are
registered trademarks of Bristol-Myers Squibb Company and
licensed exclusively in the U.S. to Elan Pharmaceuticals, Inc.
An effective non-opioid treatment option
for severe chronic pain
The PRIALT difference
PRIALT is the first intrathecal analgesic approved in February
2005 by EC along with the US approval in December 2004.
PRIALT is indicated for the management of severe chronic
pain in patients for whom intrathecal (IT) therapy is warranted,
and who are intolerant of or refractory to other treatment, such
as systemic analgesics, adjunctive therapies or IT morphine.
PRIALT is for use only in the Medtronic SynchroMed® EL,
SynchroMed® II Infusion System
and the CADD-Micro® ambulatory infusion pump.
PRIALT® is a registered trademark of Elan Pharmaceuticals,
Inc.
SynchroMed® is a registered trademark of Medtronic, Inc.
CADD-Micro® is a registered trademark of the Smiths Medical
family of companies.
An effective non-opioid treatment
option for severe chronic pain
The PRIALT difference
PRIALT is the first intrathecal analgesic approved in the
United States in more than two decades.
PRIALT is indicated for the management of severe chronic pain in
patients for whom intrathecal (IT) therapy is warranted, and who
are intolerant of or refractory to other treatment, such as systemic
analgesics, adjunctive therapies or IT morphine.
PRIALT is for use only in the Medtronic SynchroMed® EL,
SynchroMed® II Infusion System
and the CADD-Micro® ambulatory infusion pump.
PRIALT® is a registered trademark of Elan Pharmaceuticals, Inc.
SynchroMed® is a registered trademark of Medtronic, Inc.
CADD-Micro® is a registered trademark of the Smiths Medical
family of companies.
Pipeline and Products
Elan Corporation, plc is a neuroscience based biotechnology
company that is focused on discovering, developing, manufacturing
and marketing advanced therapies in neurodegeneration,
autoimmune diseases and severe pain.
TYSABRI (Crohn's Disease, Rheumatoid Arthritis) and PRIALT
(non-opioid analgesic) are registered trademarks of Elan
Pharmaceuticals, Inc.
AZACTAM and MAXIPIME (Infectious Diseases )are registered
trademarks of Bristol-Myers Squibb Company and licensed
exclusively in the U.S.to Elan Pharmaceuticals, Inc.
© 2003 Elan Pharmaceuticals, Inc. ELN 022 0104.
Last Updated February 22, 2005
NanoCrystal™ Technology
For poorly water soluble compounds, Elan's proprietary
NanoCrystal technology can enable formulation and improve
compound activity and final product characteristics. The
NanoCrystal technology can be incorporated into all dosage
forms both parenteral and oral, including solid, liquid, fast-melt,
pulsed release and controlled release dosage forms.
• Commercial Approvals for NanoCrystal Technology
• The first United States approval of a product produced
incorporating the NanoCrystal technology occurred in August
2000: Wyeth’s first solid-dose formulation of the
immunosuppressant Rapamune® (sirolimus) received
marketing approval from the U.S. Food & Drug Administration
(FDA).
• Emend® (aprepitant, MK 869) was approved by the FDA in
March 2003 and launched in the United States by Merck in
April 2003.
2005 Japanese Patent Office Issues
Patent Certificate to Elan for Its
NanoCrystal-TM- Technology
 2005 Elan's Proprietary NanoCrystal®
Technology is Used by Johnson &
Johnson Pharmaceutical Research &
Development, L.L.C. (J&J PRD) in
Phase III Clinical Trial of Paliperidone
Palmitate.
 2004 Elan NanoSystems licenses
NanoCrystal™ technology to Aventis

2004 Elan NanoSystems
licenses NanoCrystal™
technology to Roche
2003 Elan's NanoSystems
licenses NanoCrystal® to
Janssen
2003 Elan's NanoSystems
and Bristol-Myers Squibb
sign license a license
agreement for
NanoCrystal™ technology.
NanoCrystal™ Technology
For poorly water soluble compounds, Elan's proprietary NanoCrystal technology
can enable formulation and improve compound activity and final product
characteristics. The NanoCrystal technology can be incorporated into all dosage
forms both parenteral and oral, including solid, liquid, fast-melt, pulsed release
and controlled release dosage forms.

Commercial Approvals for NanoCrystal Technology
 The first United States approval of a product produced incorporating the
NanoCrystal technology occurred in August 2000: Wyeth’s first solid-dose
formulation of the immunosuppressant Rapamune® (sirolimus) received
marketing approval from the U.S. Food & Drug Administration (FDA).
Rapamune was previously available only as an oral solution in bottles or
sachets. The oral solution requires refrigeration storage, and must be mixed
with water or orange juice prior to administration. The new tablet developed
with NanoCrystal technology provides patients with more convenient
administration and storage than Rapamune oral solution. The development of
a NanoCrystal dispersion of sirolimus enabled the preparation of a solid dose
formulation.
 Emend® (aprepitant, MK 869) was approved by the FDA in March 2003 and
launched in the United States by Merck in April 2003. Emend is a capsule
containing 80 or 125 mg of aprepitant formulated as NanoCrystal drug
particles. Whereas the first commercial product that utilized NanoCrystal
technology (Rapamune) was a reformulation of an already marketed drug,
Emend was developed as an NCE in a NanoCrystal formulation.
 In 2004 Elan Licenses Its NanoCrystal Technology to Roche.
QLT USA, Inc.

Octreotide
Octreotide is being developed by QLT's wholly owned
subsidiary, QLT USA, Inc. and makes use of QLT's Atrigel®
extended-release technology to gradually deliver the drug
therapy over a specified period of time.
Octreotide and Atrigel's advantages may include high
bioavailability and the requirement for small volume injections
that are less painful than the current practice of intramuscular
injection and leave no muscle damage or scarring.
We plan on conducting clinical trials to evaluate both onemonth and three-month formulations of octreotide in Atrigel to
treat carcinoid tumors syndrome and acromegaly. We are also
exploring the drug's potential in treating the diabetic eye
disease known as diabetic retinopathy.
Patent protection for Atrigel/octreotide is expected up to 2020
and beyond.
Neurotech S.A. France
Novel Therapies for the eye - ECT Technology






Neurotech's core technology platform is
Encapsulated Cell Technology (ECT).
ECT implants consist of cells that have been
genetically modified to produce a desired
therapeutic factor (CNTF-ciliary neurotrophic
factor) that are encapsulated in a section of semipermeable hollow fiber membrane.
ECT therefore enables the controlled, continuous
long-term protein delivery (18 months) in the
vitreous cavity of the eye of therapeutic factors
directly to the retina, bypassing the blood-retina
barrier:
neurotrophic factors for the treatment of retinal
degeneration in Retinitis Pigmentosa (RP),
Geographic Atrophy (serious condition
associated with the Dry form of Age-related
Macular Degeneration), Glaucoma, Retinal Vein
Occlusion and others.
anti-angiogenic factors for the treatment of
vascular proliferation in Diabetic Retinopathy and
the Wet form of AMD, and for the treatment of
abnormal vascular permeability for various forms
of Macular Edema.
ECT based products can be tailored to address
the three main clinical manifestations of retinal
diseases: degeneration of photoreceptors and/or
ganglion cells in the neural retina, vascular
proliferation and inflammation.